'Anguish and the expectation of 200 workers hanging in the balance in the Pfizer plant in Catania: “deafening silence of the company and the institutions”.
In the Etna plant, penicillin-based injectable drugs are produced and there are trained and experienced workers. The drop in production involves a specific penicillin-based antibiotic for which the demand has dropped drastically, going from 12 to 15 million bottles every 12 months in the years from 2017 to 2019 up to 3 million bottles in the last year.
The production of unacceptable drugs requires a high level of specialization but the loss of some Chinese orders for Pfizer has determined the desire to reshape its commitment in Catania. So what to do? The company has aired – for some employees who would fall within the category of permanent layoffs – the possible move to the Ascoli Piceno company.
The Pfizer pharmaceutical group presented a 130 redundancy plan to the trade unions at the Catania plant . "At the end of February, the contract will not be renewed for 50 employees of Ramstad, who in fact work for Pfizer in addition to the freezing of 60 other positions pending the arrival of a new machine after which the units will be reduced to 30" they made known Filctem Cgil, Femca Cisl and Uiltec Uil, after a meeting with the company. The trade unions announced that "initiatives and mobilizations will start from today in view of the strike on March 4". The Catania plant specializes in the production of first-line parenteral antibiotics for hospital use, penicillin and non-penicillin
The announcement of the redundancies comes as the group is grinding billions in revenues and profits thanks to the vaccine against Covid, developed together with the German BioNtech, now dominant on the market . A drug for which the companies have received substantial public aid in various forms. During the year Pfizer has repeatedly revised upwards its estimates on revenues and profits thanks to the sale of vaccines. The data for the fourth quarter and for the whole of 2021 will be released on February 8th. In the first 9 months of 2021, the company recorded revenues of 57 billion dollars (50 billion euros), 91% more than in the same period of 2020. Vaccine receipts rose from 4.5 to almost 29 in one year. billions of dollars. Over the past year, the company's stock market value has grown by 51% to $ 295 billion. (source: https://www.ilfattoquotidiano.it/2022/02/04/pfizer-incassi-da-capogiro-con-i-vaccini-ma-nel-sito-di-catania-arrivano-130-licenziamenti/6481583 /)
———————————————————————————————————————————-
In summary, Pfizer is making gold cash at the vaccine mecca, flying on the magic carpet carried by the mass media and properly foraged sycophants, who continue to raise the bar on the need for perpetual inoculations. Obviously it is better for him (he agrees: they are not charities) to cut the redundancies in the factories that produce drugs that are now out of fashion. You use penicillin once and you have saved the patient, and they don't want to save the patient, but they want to keep him in a paranoid waiting state, inject him healthy, perpetually. These are the methods that give the certainty of safe investments on the stock exchange on companies that can only increase their profits exponentially, perpetually. And don't dare to talk about preventive care, otherwise the business will fade. And we don't want to piss off investors, right?
Thanks to our Telegram channel you can stay updated on the publication of new articles of Economic Scenarios.
⇒ Register now ⇐
Pfizer article: take the money, fire and run? 200 redundancies in the Catania plant comes from ScenariEconomici.it .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/pfizer-prendi-i-soldi-licenzia-e-scappa-200-esuberi-nello-stabilimento-di-catania/ on Tue, 08 Feb 2022 10:39:04 +0000.
